BRIEF

on GENSIGHT BIOLOGICS S.A. (EPA:SIGHT)

GenSight Biologics raises €1.1 million from its shareholders

Stock price chart of GENSIGHT BIOLOGICS S.A. (EPA:SIGHT) showing fluctuations.

GenSight Biologics, a biopharmaceutical company specializing in gene therapies for retinal diseases, has announced a €1.1 million funding round. Investors Heights Capital and Invus subscribed to this capital increase through the issuance of shares and warrants. The financing is intended to support the company's ongoing operations until March 2027.

The funds raised do not require a prospectus under current European regulations, thus allowing for rapid execution. The funds will help finance the RECOVER Phase 3 clinical trial, scheduled to begin at the end of March 2027. The success of this transaction demonstrates the renewed confidence of the company's long-standing partners.

R. E.

Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.

Click here to consult the press release on which this article is based

See all GENSIGHT BIOLOGICS S.A. news